Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan)

Br J Haematol. 2020 Jan;188(2):334-337. doi: 10.1111/bjh.16305. Epub 2019 Dec 16.

Authors

Saskia Schols¹, Miles A Nunn², Ian Mackie³, Wynne Weston-Davies², Jun-Ichi Nishimura⁴, Yuzuru Kanakura⁴, Nicole Blijlevens¹, Petra Muus^{1

5}, Saskia Langemeijer¹

Affiliations

¹ Department of Hematology, Radboudumc, Nijmegen, The Netherlands.
² Akari Therapeutics, London, UK.
³ Haemostasis Research unit, Department of Haematology, University College London, London, UK.
⁴ Department of Haematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
⁵ Department of Haematology, King's College Hospital, London, UK.

PMID: 31840801
DOI: 10.1111/bjh.16305

No abstract available

Keywords: complement; coversin; haemolysis; nomacopan; paroxysmal nocturnal haemoglobinuria.

Publication types

Case Reports

MeSH terms

Adult
Animals
Antibodies, Monoclonal, Humanized / therapeutic use*
Complement C5 / antagonists & inhibitors*
Complement Inactivating Agents / therapeutic use*
Drug Resistance
Hemoglobinuria, Paroxysmal / drug therapy*
Humans
Male
Recombinant Proteins / therapeutic use*

Substances

Antibodies, Monoclonal, Humanized
Complement C5
Complement Inactivating Agents
Recombinant Proteins
eculizumab